Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine

NCT05142488 · clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
662
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)